H.R. 5429 · 118th Congress

Medication Affordability and Patent Integrity Act

Introduced on Sep 13, 2023 by Ann M. Kuster (D-NH-2). One cosponsor. Latest action (Sep 15, 2023): Referred to the Subcommittee on Health.

Stage
Introduced
Introduced
Sep 13, 2023
Cosponsors
1
1 from the other party
Policy area
Commerce
Open in the Congress explorerCongress.govAlert me

Progress

The furthest stage the measure reached. Simple and concurrent resolutions do not go to the President.

  1. Introduced
  2. 2Reported by committee
  3. 3Passed one chamber
  4. 4Passed both chambers
  5. 5Sent to the President
  6. 6Became law

Official title

To require sponsors of drug applications and holders of approved applications to provide certain submissions and communications to the Food and Drug Administration and the United States Patent and Trademark Office.

Subjects

  • Drug safety, medical device, and laboratory regulation
  • Inflation and prices
  • Intellectual property
  • Manufacturing
  • Prescription drugs

Summary

The Congressional Research Service has not summarized this measure yet.

Sponsor and cosponsors

Cosponsors by party as of the day they signed on. Original cosponsors signed on the day of introduction.

Ann M. KusterD-NH-2Sponsor

Republicans · 1

Roll calls

Recorded votes on the measure. Most measures move by voice vote or unanimous consent, which record no individual positions.

No recorded roll call on this measure: it moved by voice vote or unanimous consent, or has not reached the floor.

History

Every action as published, oldest first. Roll calls link to how each member voted.

  1. Sep 13, 2023Introduced in House
  2. Sep 13, 2023Introduced in House
  3. Sep 13, 2023 · HouseReferred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
  4. Sep 13, 2023 · HouseReferred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
  5. Sep 15, 2023 · HouseReferred to the Subcommittee on Health.

Committees

Committees and subcommittees the measure was referred to.

Agencies in its committees' jurisdiction

Analisa's mapping of committee jurisdiction to federal agencies; the bill may touch others, or none of these.

Who lobbied on it

Organizations whose lobbying reports (LD-2) name this measure. Spending is what they reported for those quarters on all issues, not on this measure alone.

  1. VIATRIS INC.7 reports
    $1.2M reported (all issues)
  2. ASSOCIATION FOR ACCESSIBLE MEDICINES5 reports
    $3M reported (all issues)
  3. Fresenius Kabi USA LLC5 reports
    Federal contractor: FRESENIUS KABI USA, LLCAI match · 100%
  4. GSK (fka GLAXOSMITHKLINE INC.)5 reports
    $6.3M reported (all issues)
  5. PHARMACEUTICAL RESEARCH & MANUFACTURERS OF AMERICA5 reports
    $37.4M reported (all issues)
  6. KAISER FOUNDATION HEALTH PLAN INC.3 reports
    $3.7M reported (all issues)Federal contractor: KAISER FOUNDATION HEALTH PLAN OF WASHINGTONAI match · 97%
  7. AARP2 reports
    $10M reported (all issues)
  8. AMNEAL PHARMACEUTICALS INC.2 reports
    $440K reported (all issues)Federal contractor: AMNEAL PHARMACEUTICALS OF NEW YORK, LLC$467.7K in contracts, FY2026AI match · 98%
  9. NOVARTIS CORPORATION2 reports
    $1.5M reported (all issues)Federal contractor: NOVARTIS PHARMACEUTICALS CORPORATION$36.2M in contracts, FY2026AI match · 100%
  10. BIOTECHNOLOGY INNOVATION ORGANIZATION1 report
  11. BLUE CROSS AND BLUE SHIELD OF KANSAS, INC.1 report
    $10K reported (all issues)
  12. BLUE CROSS BLUE SHIELD OF MICHIGAN1 report
    $266K reported (all issues)
  13. Blue Cross and Blue Shield Association1 report
    $1.2M reported (all issues)
  14. Blue Cross and Blue Shield of Florida, Inc.1 report
    $120K reported (all issues)
  15. PFIZER INC.1 report
    $1.6M reported (all issues)Federal contractor: PFIZER INCAI match · 100%

Reports filed in 2023, 2024, 2025, 2026.

Sources and method

Every figure on this page traces to these records.

  • Bill status: bills and resolutions, sponsors, actions, subjects and CRS summaries (U.S. Government Publishing Office (GovInfo), from Congress.gov (Library of Congress))GovInfo Bill Status bulk data (Congress.gov; summaries by the Congressional Research Service) · data current to Oct 6, 2026 · loaded Oct 6, 2026 · license: Public domain (U.S. Government work, 17 U.S.C. § 105)
  • Members of Congress, their terms, committees and identifiers (The @unitedstates project (from the Biographical Directory of the U.S. Congress, the House and the Senate))unitedstates/congress-legislators: legislators, committees and current committee membership · data current to Oct 3, 2026 · loaded Oct 3, 2026 · license: CC0 1.0 (public domain dedication)
  • House roll-call votes (Office of the Clerk, U.S. House of Representatives)Office of the Clerk, U.S. House of Representatives, roll-call vote records · data current to Oct 3, 2026 · loaded Oct 3, 2026 · license: Public domain (U.S. Government work, 17 U.S.C. § 105)
  • Senate roll-call votes and DW-NOMINATE scores (Voteview (UCLA Department of Political Science))Lewis, Jeffrey B., Keith Poole, Howard Rosenthal, Adam Boche, Aaron Rudkin, and Luke Sonnet (2026). Voteview: Congressional Roll-Call Votes Database. https://voteview.com/ · data current to Oct 3, 2026 · loaded Oct 3, 2026 · license: Free to use with the required citation
  • Lobbying disclosures (LD-1 registrations, LD-2 quarterly reports, LD-203 contribution reports) (Clerk of the U.S. House of Representatives)Clerk of the House, Lobbying Disclosure Act filings (organizations only; lobbyists' names are not loaded) · data current to Oct 6, 2026 · loaded Oct 6, 2026 · license: Public domain (U.S. Government work, 17 U.S.C. § 105)
  • Positions are shown only where a roll call recorded them; voice votes and unanimous consent record none.
  • Money and votes are shown side by side; neither explains the other.